JP2016521979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521979A5 JP2016521979A5 JP2016516815A JP2016516815A JP2016521979A5 JP 2016521979 A5 JP2016521979 A5 JP 2016521979A5 JP 2016516815 A JP2016516815 A JP 2016516815A JP 2016516815 A JP2016516815 A JP 2016516815A JP 2016521979 A5 JP2016521979 A5 JP 2016521979A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- amplicon
- patient
- gene
- rna transcript
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 108091093088 Amplicon Proteins 0.000 claims description 20
- 239000000523 sample Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 12
- 206010038389 Renal cancer Diseases 0.000 claims description 12
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 12
- 201000010982 kidney cancer Diseases 0.000 claims description 12
- 102100036517 Apolipoprotein L domain-containing protein 1 Human genes 0.000 claims description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 10
- 108010062802 CD66 antigens Proteins 0.000 claims description 10
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 10
- 102000017930 EDNRB Human genes 0.000 claims description 10
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 claims description 10
- 102100020997 Fractalkine Human genes 0.000 claims description 10
- 101000928701 Homo sapiens Apolipoprotein L domain-containing protein 1 Proteins 0.000 claims description 10
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 10
- 101000967299 Homo sapiens Endothelin receptor type B Proteins 0.000 claims description 10
- 101000678280 Homo sapiens Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 claims description 10
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 claims description 10
- 101001003581 Homo sapiens Lamin-B1 Proteins 0.000 claims description 10
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 claims description 10
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 claims description 10
- 101000788517 Homo sapiens Tubulin beta-2A chain Proteins 0.000 claims description 10
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 102100026517 Lamin-B1 Human genes 0.000 claims description 10
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 claims description 10
- 102100025225 Tubulin beta-2A chain Human genes 0.000 claims description 10
- 230000032823 cell division Effects 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 238000010606 normalization Methods 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- -1 PPA2B Proteins 0.000 claims description 6
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims description 5
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims description 5
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims description 5
- 101001126234 Homo sapiens Phospholipid phosphatase 3 Proteins 0.000 claims description 4
- 102100030450 Phospholipid phosphatase 3 Human genes 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000012520 frozen sample Substances 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829100P | 2013-05-30 | 2013-05-30 | |
| US61/829,100 | 2013-05-30 | ||
| PCT/US2014/040003 WO2014194078A1 (en) | 2013-05-30 | 2014-05-29 | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018134242A Division JP2018161151A (ja) | 2013-05-30 | 2018-07-17 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521979A JP2016521979A (ja) | 2016-07-28 |
| JP2016521979A5 true JP2016521979A5 (enExample) | 2017-04-27 |
Family
ID=51989393
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516815A Pending JP2016521979A (ja) | 2013-05-30 | 2014-05-29 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
| JP2018134242A Pending JP2018161151A (ja) | 2013-05-30 | 2018-07-17 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
| JP2020138078A Active JP7301798B2 (ja) | 2013-05-30 | 2020-08-18 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018134242A Pending JP2018161151A (ja) | 2013-05-30 | 2018-07-17 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
| JP2020138078A Active JP7301798B2 (ja) | 2013-05-30 | 2020-08-18 | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10181008B2 (enExample) |
| EP (2) | EP3004392B1 (enExample) |
| JP (3) | JP2016521979A (enExample) |
| AU (2) | AU2014274135B2 (enExample) |
| CA (2) | CA2903878C (enExample) |
| DK (1) | DK3004392T3 (enExample) |
| ES (1) | ES2829415T3 (enExample) |
| IL (2) | IL240919B (enExample) |
| MX (2) | MX369911B (enExample) |
| SG (2) | SG10201709537PA (enExample) |
| WO (1) | WO2014194078A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018187767A1 (en) * | 2017-04-06 | 2018-10-11 | The Regents Of The University Of California | Predicting, diagnosing, and treating nausea and vomiting of pregnancy |
| AU2018348249A1 (en) * | 2017-10-12 | 2020-04-16 | Nantomics, Llc | Cancer score for assessment and response prediction from biological fluids |
| EP3874274B1 (en) | 2018-10-31 | 2024-01-03 | Regents of the University of Minnesota | Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer |
| KR102280204B1 (ko) * | 2018-12-13 | 2021-07-21 | 연세대학교 산학협력단 | 신장 세포 암의 종양의 병리학적 등급에 대한 정보를 제공하기 위한 방법 및 장치 |
| WO2020146745A1 (en) * | 2019-01-11 | 2020-07-16 | Quadrus Medical Technologies, Inc. | Systems and methods for assessing and evaluating renal health diagnosis, staging, and therapy recommendation |
| EP3978629A1 (en) * | 2020-10-01 | 2022-04-06 | Koninklijke Philips N.V. | Prediction of an outcome of a bladder or kidney cancer subject |
| CN113593640B (zh) * | 2021-08-03 | 2023-07-28 | 哈尔滨市米杰生物科技有限公司 | 一种鳞癌组织功能状态与细胞组分评估方法及系统 |
| WO2025085824A1 (en) * | 2023-10-20 | 2025-04-24 | Memorial Sloan-Kettering Cancer Center | Multi-scale analysis of ribonucleic acid sequence data for predicting responses to anti-cancer therapies |
| CN117935910B (zh) * | 2024-01-26 | 2024-09-17 | 华中农业大学 | 玉米snp位点的筛选方法、装置、电子设备及介质 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7135314B1 (en) | 1997-04-17 | 2006-11-14 | Cell Therapeutics, Inc. | Human phosphatidic acid phosphatase |
| JP2003519491A (ja) | 2000-01-13 | 2003-06-24 | ジェネンテック・インコーポレーテッド | 新規なｓｔｒａ６ポリペプチド |
| US6475855B1 (en) | 2000-03-01 | 2002-11-05 | Micron Technology, Inc. | Method of forming integrated circuitry, method of forming a capacitor and method of forming DRAM integrated circuitry |
| DE10126344A1 (de) | 2000-07-14 | 2002-01-24 | Max Planck Gesellschaft | Apoptose-induzierende DNA-Sequenzen |
| WO2002027028A1 (en) | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| WO2002074237A2 (en) | 2001-03-19 | 2002-09-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CA2442820A1 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
| JP2005500832A (ja) | 2001-06-18 | 2005-01-13 | ロゼッタ・インファーマティクス・インコーポレーテッド | 乳癌患者の診断および予後 |
| US7470509B2 (en) | 2002-02-08 | 2008-12-30 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
| EP2241636A1 (en) | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20060183120A1 (en) | 2002-10-04 | 2006-08-17 | Teh Bin T | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
| JP2006514554A (ja) | 2002-11-21 | 2006-05-11 | ワイス | 腎細胞癌および他の固形腫瘍の診断法 |
| EP1618218A2 (en) | 2003-04-29 | 2006-01-25 | Wyeth | Methods for prognosis and treatment of solid tumors |
| ES2787475T3 (es) | 2003-06-24 | 2020-10-16 | Genomic Health Inc | Predicción de probabilidad de recurrencia del cáncer |
| EP1644522A2 (en) | 2003-07-02 | 2006-04-12 | Novartis AG | Genes regulated in ovarian cancer as prognostic and therapeutic targets |
| US20050002904A1 (en) | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| EP1644858B1 (en) * | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| JP2005211023A (ja) | 2004-01-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | 腎細胞癌の転移若しくは再発の可能性を予測する方法 |
| US20070224596A1 (en) | 2004-04-09 | 2007-09-27 | Mariana Nacht | Compositions and methods for the modifying hypoxia induced gene regulation |
| US7871769B2 (en) * | 2004-04-09 | 2011-01-18 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| WO2005108623A2 (en) * | 2004-05-04 | 2005-11-17 | Bayer Healthcare | Mn/ca ix/ ca9 and renal cancer prognosis |
| WO2005117943A2 (en) | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Biomarkers for monitoring inhibition of impdh pathway |
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| WO2006066071A2 (en) | 2004-12-17 | 2006-06-22 | Mayo Foundation For Medical Education And Research | Prognosis of renal cell carcinoma |
| CA2596469A1 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services | Biomarkers for tissue status |
| WO2006089185A2 (en) | 2005-02-18 | 2006-08-24 | Wyeth | Pharmacogenomic markers for prognosis of solid tumors |
| US20090186024A1 (en) | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
| WO2006124022A1 (en) | 2005-05-13 | 2006-11-23 | Vanandel Research Institute | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma |
| US20070037186A1 (en) | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| CA2611728A1 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2006135886A2 (en) | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006138275A2 (en) | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| CN101228134A (zh) | 2005-06-15 | 2008-07-23 | 辉瑞有限公司 | 用作杀寄生虫剂的取代芳基吡唑 |
| WO2007026896A1 (ja) | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 |
| CN101292046B (zh) | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
| EP2332984A3 (en) | 2005-09-30 | 2011-10-12 | Universiteit Maastricht | Tumor angiogenesis associated genes and a method for their identification |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| WO2007072225A2 (en) | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| KR20080087822A (ko) | 2005-12-16 | 2008-10-01 | 제넨테크, 인크. | 신경아교종을 진단하고, 예측하고, 치료하는 방법 |
| US20080242606A1 (en) | 2006-06-06 | 2008-10-02 | Zhong Jiang | Use of IMP3 as a Prognostic Marker for Cancer |
| CA2660275A1 (en) | 2006-08-10 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| US9034574B2 (en) * | 2006-12-27 | 2015-05-19 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20080286273A1 (en) | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
| EP1990417A1 (en) | 2007-05-11 | 2008-11-12 | Universität Bayreuth | Archaeal plasmid vector system |
| WO2009105640A1 (en) | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| CA3153682A1 (en) | 2008-11-17 | 2010-05-20 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| WO2010149640A2 (en) | 2009-06-26 | 2010-12-29 | Noviogendix Research B.V. | Molecular markers in kidney cancer |
| US9005891B2 (en) | 2009-11-10 | 2015-04-14 | Genomic Health, Inc. | Methods for depleting RNA from nucleic acid samples |
| EP3739060A1 (en) * | 2009-11-23 | 2020-11-18 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
| DK3178944T3 (da) | 2010-01-11 | 2019-08-12 | Genomic Health Inc | Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer |
| KR20140072014A (ko) * | 2011-06-16 | 2014-06-12 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| CA2843756A1 (en) | 2011-08-22 | 2013-02-28 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
-
2014
- 2014-05-29 CA CA2903878A patent/CA2903878C/en active Active
- 2014-05-29 AU AU2014274135A patent/AU2014274135B2/en active Active
- 2014-05-29 SG SG10201709537PA patent/SG10201709537PA/en unknown
- 2014-05-29 MX MX2015012782A patent/MX369911B/es active IP Right Grant
- 2014-05-29 EP EP14804772.3A patent/EP3004392B1/en active Active
- 2014-05-29 US US14/779,428 patent/US10181008B2/en active Active
- 2014-05-29 ES ES14804772T patent/ES2829415T3/es active Active
- 2014-05-29 CA CA3093128A patent/CA3093128C/en active Active
- 2014-05-29 EP EP20198766.6A patent/EP3825420A1/en not_active Withdrawn
- 2014-05-29 WO PCT/US2014/040003 patent/WO2014194078A1/en not_active Ceased
- 2014-05-29 JP JP2016516815A patent/JP2016521979A/ja active Pending
- 2014-05-29 SG SG11201506987VA patent/SG11201506987VA/en unknown
- 2014-05-29 DK DK14804772.3T patent/DK3004392T3/da active
-
2015
- 2015-08-30 IL IL240919A patent/IL240919B/en active IP Right Grant
- 2015-09-14 MX MX2019013953A patent/MX2019013953A/es unknown
-
2018
- 2018-07-17 JP JP2018134242A patent/JP2018161151A/ja active Pending
- 2018-11-26 US US16/199,707 patent/US20190095575A1/en not_active Abandoned
-
2020
- 2020-07-06 AU AU2020204502A patent/AU2020204502B2/en active Active
- 2020-08-18 JP JP2020138078A patent/JP7301798B2/ja active Active
- 2020-11-02 US US17/086,850 patent/US11551782B2/en active Active
-
2021
- 2021-05-30 IL IL283548A patent/IL283548A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521979A5 (enExample) | ||
| Wang et al. | Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer | |
| Dama et al. | Biomarkers and lung cancer early detection: state of the art | |
| JP2016214245A5 (enExample) | ||
| JP2017055769A5 (enExample) | ||
| KR101896545B1 (ko) | 유방암 환자의 예후 예측 방법 | |
| Hofbauer et al. | A urinary microRNA (miR) signature for diagnosis of bladder cancer | |
| JP2019162150A5 (enExample) | ||
| JP2010538609A5 (enExample) | ||
| NZ719474A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| Kozminsky et al. | Detection of CTC clusters and a dedifferentiated RNA‐expression survival signature in prostate cancer | |
| WO2012015765A3 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| FI3117216T3 (fi) | Menetelmä kiinteäkasvaimisen syövän tunnistamiseksi | |
| JP2009523028A5 (enExample) | ||
| JP2017508970A5 (enExample) | ||
| Marín-Aguilera et al. | Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer | |
| JP2014144959A5 (enExample) | ||
| JP2020501517A5 (enExample) | ||
| JP2016537010A5 (enExample) | ||
| JP2018527886A5 (enExample) | ||
| KR101950717B1 (ko) | 유방암 환자의 화학치료 유용성 예측 방법 | |
| Eickelschulte et al. | Biomarkers for the detection and risk stratification of aggressive prostate cancer | |
| JP2016536004A5 (enExample) | ||
| KR20180057097A (ko) | 유방암 환자의 예후 예측 방법 | |
| JP2010523134A (ja) | Ｅｇｆｒ／ｃｓｆ−１／ｃａｉｘ発現に基づき非小細胞肺癌の化学療法計画および生存余命を決定する方法 |